Abstract
Electronic self-reporting of adverse events for patients undergoing cancer treatment: the eRAPID research programme including two RCTs
Highlights
To help to understand the value of the eRAPID system in supporting patient care during systematic cancer treatment, a qualitative substudy was embedded within the randomised controlled trials (RCTs)
Conclusions and reflections on delivering the eRAPID information technology work package Over a period of 2 years, we successfully implemented and maintained the eRAPID IT system at the Leeds, Manchester and Bristol sites to support the delivery of the systemic RCT and pilot trials in the radiotherapy and surgical arms
EuroQol-5 Dimensions (EQ-5D)-5L scores decreased over the trial period in both arms, but scores were higher at each time point in the eRAPID arm than in the usual-care arm
Summary
To help to understand the value of the eRAPID system in supporting patient care during systematic cancer treatment, a qualitative substudy was embedded within the RCT. Radiotherapy AEs are reported by clinicians; the timing and accuracy of reporting and clinician–patient communication can be improved by asking patients to report their own symptoms via PROMs. Well-timed and appropriate documentation of AEs throughout the patient journey is essential to both understand the toxicity profile of the treatments and comprehensively support patients.[105] eRAPID is a programme to develop, evaluate and implement an online system for reporting and managing AEs during cancer treatment, developed for use with radiotherapy patients, including those receiving radical treatment to the prostate. This research programme developed and evaluated an electronic system, called eRAPID, for cancer patients to remotely self-report adverse events. An economic evaluation was conducted to estimate the cost-effectiveness of the eRAPID system for AE reporting from home or hospital compared with usual care for patients receiving systemic treatment (chemotherapy or targeted therapies) for colorectal, breast or gynaecological cancers. The analysis was guided by the recommendations of the NICE methods guide.[146]
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
